Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury.
Overview
- Laboratory of Pharmaceutics, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan
- Center for Clinical Research, Hamamatsu University Hospital, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka 431-3192, Japan
- Department of Clinical Pharmacology, Graduate School of Biomedical Sciences, Tokushima University, 1-78-1, Shoumachi, Tokushima 770-8505, Japan
- Laboratory of Pharmacology, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan
Abstract
Inflammatory responses centered on microglial activation are deeply involved in the progression of cerebral ischemia-reperfusion injury, and RelA, a subunit of nuclear factor κB (NF-κB), acts as a central mediator of these responses. In this study, we evaluated the efficacy of a nose-to-brain drug delivery system that combines intranasal administration with polymeric nanomicelles modified with the cell-penetrating peptide Tat (polyethylene glycol [PEG]-polycaprolactone [PCL]-Tat) to deliver RelA-targeting small interfering RNA (siRNA), referred to as siRelA. The PEG-PCL-Tat-siRelA complex exhibited efficient intracellular uptake by BV-2 microglial cells and significantly suppressed RelA mRNA expression. No significant cytotoxicity was observed in BV-2 or primary cultured mouse hippocampal neurons. In addition, the complex showed high siRNA stability in the cerebrospinal fluid. Using a radiolabeled model siRNA, intranasal administration of PEG-PCL-Tat to mice subjected to transient middle cerebral artery occlusion (t-MCAO) significantly enhanced siRNA distribution in ischemic brain regions. Intranasal administration of PEG-PCL-Tat-siRelA significantly reduced the infarct volume in ischemic brain regions of the t-MCAO model mice. Furthermore, suppression of RelA mRNA expression in ischemic brain tissue was accompanied by significant reductions in the mRNA expression of NF-κB-downstream inflammatory cytokines. Taken together, these results suggest that intranasal delivery of siRelA using PEG-PCL-Tat represents a promising novel neuroprotective therapeutic strategy mediated by the modulation of inflammatory responses.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.
The paper's code and data availability statement is in the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.
Data
No dataset and no data link were found in the paper.
Data and code availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. All relevant data are included within the article and its supplemental information files.
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 2, 28 September 2026
- Authors: added Mitsuyoshi Fukuda (0009-0007-4383-9702); Takayuki Oguma (0009-0007-7046-9620); Taiki Nagatomo (0009-0005-2730-1297); removed Mitsuyoshi Fukuda; Takayuki Oguma; Taiki Nagatomo
- Funding: added Japan Society for the Promotion of Science
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 7 authors, 9 keywords, 72 references.
Cite
This paper
Fukuda, M., Oguma, T., Nagatomo, T., Yamaguchi, T., Kosuge, Y., Suzuki, T., & Kanazawa, T. (2026). Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury. Molecular therapy. Nucleic acids, 37(3), 103028. https://
BibTeX
@article{fukuda2026intra
author = {Fukuda, Mitsuyoshi and Oguma, Takayuki and Nagatomo, Taiki and Yamaguchi, Taiki and Kosuge, Yasuhiro and Suzuki, Toyofumi and Kanazawa, Takanori},
title = {{Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury}},
journal = {Molecular therapy. Nucleic acids},
year = {2026},
month = jul,
volume = {37},
number = {3},
pages = {103028},
publisher = {American Society of Gene \& Cell Therapy},
issn = {2162-2531},
doi = {10.1016/
url = {https://
pmid = {42602868},
pmcid = {PMC13475413}
}
RIS
TY - JOUR
AU - Fukuda, Mitsuyoshi
AU - Oguma, Takayuki
AU - Nagatomo, Taiki
AU - Yamaguchi, Taiki
AU - Kosuge, Yasuhiro
AU - Suzuki, Toyofumi
AU - Kanazawa, Takanori
TI - Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury
T2 - Molecular therapy. Nucleic acids
J2 - Mol Ther Nucleic Acids
PY - 2026
DA - 2026/
VL - 37
IS - 3
SP - 103028
SN - 2162-2531
PB - American Society of Gene & Cell Therapy
DO - 10.1016/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1016/
"type": "article-journal",
"title": "Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury",
"container-title": "Molecular therapy. Nucleic acids",
"author": [
{
"family": "Fukuda",
"given": "Mitsuyoshi"
},
{
"family": "Oguma",
"given": "Takayuki"
},
{
"family": "Nagatomo",
"given": "Taiki"
},
{
"family": "Yamaguchi",
"given": "Taiki"
},
{
"family": "Kosuge",
"given": "Yasuhiro"
},
{
"family": "Suzuki",
"given": "Toyofumi"
},
{
"family": "Kanazawa",
"given": "Takanori"
}
],
"container-title-short":
"volume": "37",
"issue": "3",
"page": "103028",
"DOI": "10.1016/
"PMID": "42602868",
"PMCID": "PMC13475413",
"ISSN": "2162-2531",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
21
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3389/frai.2024.1369702 [code]
- Deep learning for prediction of post-thrombectomy outcomes based on admission CT angiography in large vessel occlusion stroke.Journal: Frontiers in artificial intelligenceIn common: stroke, 3 references
- [2] doi:10.1038/s41598-023-42961-x [code]
- Non-inferiority of deep learning ischemic stroke segmentation on non-contrast CT within 16-hours compared to expert neuroradiologists.Journal: Scientific reportsIn common: stroke, 3 references
- [3] doi:10.4252/wjsc.v17.i9.110663
- Combined mesenchymal and neural stem cell therapy enhances neurological recovery in cerebral infarction.Journal: World journal of stem cellsIn common: stroke, 2 references
- [4] doi:10.1038/s41746-025-01703-1 [code]
- Machine learning to predict penumbra core mismatch in acute ischemic stroke using clinical note data.Journal: NPJ digital medicineIn common: stroke, 2 references
- [5] doi:10.3390/brainsci14030244
- Oxygen-Glucose Deprivation Increases NR4A1 Expression and Promotes Its Extranuclear Translocation in Mouse Astrocytes.Journal: Brain sciencesIn common: mouse, cellular / molecular, 2 references
- [6] doi:10.3390/antib10040047
- Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration.Journal: Antibodies (Basel, Switzerland)In common: 2 references
- [7] doi:10.1007/s00018-023-04911-8
- The COP9 signalosome reduces neuroinflammation and attenuates ischemic neuronal stress in organotypic brain slice culture model.Journal: Cellular and molecular life sciences : CMLSIn common: stroke, mouse, cellular / molecular, 1 reference
- [8] doi:10.1038/s41598-024-68462-z
- Astragaloside IV protects brain cells from ischemia-reperfusion injury by inhibiting ryanodine receptor expression and reducing the expression of P-Src and P-GRK2.Journal: Scientific reportsIn common: stroke, mouse, cellular / molecular, 1 reference
- [9] doi:10.1186/s12868-023-00775-7
- Influence of sex, age and diabetes on brain transcriptome and proteome modifications following cerebral ischemia.Journal: BMC neuroscienceIn common: stroke, mouse, cellular / molecular, 1 reference
- [10] doi:10.3389/fnins.2022.869081
- The Alteration Profiles of m<sup>6</
sup>A-Tagged circRNAs in the Peri-Infarct Cortex After Cerebral Ischemia in Mice. Journal: Frontiers in neuroscienceIn common: stroke, mouse, cellular / molecular, 1 reference
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
